Search details
1.
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Br J Haematol
; 202(1): 40-47, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36971061
2.
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Ann Hematol
; 102(4): 811-817, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36847805
3.
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
Eur J Clin Invest
; 51(4): e13421, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33022756
4.
Pulmonary damage in a patient with hairy cell leukemia - infectious involvement or hematological disease activity? Case report.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 167(4): 385-389, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-35713332
5.
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.
Cancer Med
; 12(6): 6956-6970, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36440594
6.
High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serum.
J Pharm Biomed Anal
; 219: 114923, 2022 Sep 20.
Article
in English
| MEDLINE | ID: mdl-35830774
7.
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
Cancers (Basel)
; 13(13)2021 Jun 23.
Article
in English
| MEDLINE | ID: mdl-34201565
Results
1 -
7
de 7
1
Next >
>>